Imagion Biosystems has announced “Appendix 3B, New issue announcement, application for quotation of additional securities and agreement.”
Read Appendix 3B.
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.